Genome-wide biomarker analysis across the full spectrum of HER2-expressing breast cancers to reveal a clonal chromosome 17 imbalance defining unfavourable HER2-low disease

Résumé fourni par la source

BACKGROUND: The full spectrum of HER2-expressing breast carcinomas (BCs) may be treated with antibody-drug conjugates (ADCs) targeting HER2. However, much remains to be learned for optimal ADC use with respect to BC heterogeneity. METHODS: We here applied shallow whole-genome sequencing (CUTseq method) to detect genome-wide copy number alterations in 157 BC patients (19 HER2-null, 21 HER2-ultralow, 84 HER2-low and 33 HER2-positive). RESULTS: CUTseq accurately detected the ERBB2 status with respect to standard methods and identified ERBB2 copy number loss in 13/157 cases (8%). HER2-null and ultralow BCs showed ‘cold’ chr17 copy number profiles, whereas HER2-low BCs comprised three distinct clusters based on chr17 and genome-wide copy number profiles. Notably, 40% of these tumours harboured a chr17 imbalance (p-arm loss/q-arm gain), which was significantly associated with poor prognosis. On four HER2-low tumours we additionally performed single-cell copy number profiling revealing that the chr17 copy number imbalance is a clonal rearrangement. CONCLUSIONS: This first in class genome-wide characterization sheds light on the heterogeneity of somatic copy number alterations and chromosomal instability across the spectrum of HER2-expressing BCs and further defines the presence of a chr17 imbalance showing a prognostic genomic feature for a subgroup of HER2-low tumours. Further studies are warranted to confirm the prognostic relevance of this genomic trait and to define whether it has an impact on stratification of response to treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.